Nitrogen

inter-alpha-trypsin inhibitor heavy chain 4 ; Homo sapiens







39 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34745128 Sequential Analysis of the N/O-Glycosylation of Heavily Glycosylated HIV-1 gp120 Using EThcD-sceHCD-MS/MS. 2021 2
2 28584151 Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity. 2017 Aug 1
3 29045410 Patterns and rates of viral evolution in HIV-1 subtype B infected females and males. 2017 1
4 26057350 HIV Subtypes B and C gp120 and Methamphetamine Interaction: Dopaminergic System Implicates Differential Neuronal Toxicity. 2015 Jun 9 1
5 26110648 The Patterns of Coevolution in Clade B HIV Envelope's N-Glycosylation Sites. 2015 1
6 24825317 Intracellular mannose binding lectin mediates subcellular trafficking of HIV-1 gp120 in neurons. 2014 Sep 2
7 24884609 Site-specific glycan microheterogeneity of inter-alpha-trypsin inhibitor heavy chain H4. 2014 Jul 3 3
8 25001301 Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study. 2014 Sep 1
9 25120578 Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection. 2014 1
10 23710622 Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. 2013 Jun 27 1
11 23748959 HIV N-linked glycosylation site analyzer and its further usage in anchored alignment. 2013 Jul 1
12 22270360 Sometimes it takes two to tango: contributions of dimerization to functions of human α-defensin HNP1 peptide. 2012 Mar 16 1
13 21248038 The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. 2011 Apr 1
14 21383973 The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. 2011 Feb 2
15 20156104 Genotypic characterization of HIV type 1 env gp160 sequences from three regions in Thailand. 2010 Feb 1
16 20164234 Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. 2010 May 1
17 20439465 Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. 2010 Jul 2 1
18 20498311 Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. 2010 Aug 2
19 20686044 Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. 2010 Oct 1
20 19113978 Development of a panel of well-characterized human immunodeficiency virus type 1 isolates from newly diagnosed patients including acute and recent infections. 2009 Jan 3
21 17050611 Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. 2007 Jan 1
22 17522223 Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. 2007 Aug 1
23 17599380 Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. 2007 Oct 10 1
24 18076768 Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. 2007 Dec 12 1
25 16912292 Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. 2006 Sep 1
26 19372833 Large-molecular-weight carbohydrate-binding agents as HIV entry inhibitors targeting glycoprotein gp120. 2006 Sep 1
27 15183057 HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity. 2004 Jun 20 1
28 15542540 Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. 2004 Oct 1
29 12941910 Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. 2003 Sep 1
30 12954207 Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. 2003 Sep 1 2
31 14581570 Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. 2003 Nov 1
32 12072497 Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. 2002 Jul 1
33 12489987 Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1. 2002 Dec 19 1
34 11007268 Selective and facile cyclization of N-chloroacetylated peptides from the C4 domain of HIV Gp120 in LiCl/DMF solvent systems. 2000 Sep 1
35 8483933 Proposed atomic structure of a truncated human immunodeficiency virus glycoprotein gp120 derived by molecular modeling: target CD4 recognition and docking mechanism. 1993 May 1 1
36 1549584 Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. 1992 Mar 15 3
37 2082620 Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity. 1990 Dec 1
38 2341393 Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. 1990 May 25 1
39 3023826 Biosynthesis and glycosylation of the epidermal growth factor receptor in human tumor-derived cell lines A431 and Hep 3B. 1986 Jan 2